New oximeter software put to the test in small study
NCT ID NCT07527000
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked how well a new software (Algo Oximeter) measures blood oxygen levels compared to standard lab tests. It involved 25 healthy adults aged 22-50 who were non-smokers. The goal was to see if the software is accurate enough for safe use in monitoring oxygen saturation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
25 people
The number who actually took part.
- Started
-
Apr 2026
- Finished
-
May 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study will include a minimum of 24 healthy volunteers.
- Ages
-
22 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant must have the ability to understand and provide written informed consent. * Participant is adult 22-50 years of age. * Participant must be willing and able to comply with study procedures and duration. * Participant is a non-smoker or who has not smoked within 2 days prior to the study. * Male or female of any race. Exclusion Criteria: * Participant has a resting SpO2 \< 92% as assessed by a pulse oximeter * Participant is considered as being morbidly obese (defined as BMI \>39.5) * Compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.) * Females who are pregnant * Females who are trying to get pregnant with confirmation of positive urine pregnancy test * Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels \>3% as assessed with a Masimo Radical 7 (Rainbow) * Participants with known respiratory conditions such as: (self-reported) * uncontrolled / severe asthma, * flu, * pneumonia / bronchitis, * shortness of breath / respiratory distress, * unresolved respiratory or lung surgery, * emphysema, COPD, lung disease * Recent COVID with hospitalization * Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review) * high blood pressure: systolic \>140 mmHg or diastolic \>90 mmHg on 3 consecutive readings (reviewed during health screen) * have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA) * chest pain (angina) * heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen) * previous heart attack * blocked artery * unexplained shortness of breath * congestive heart failure (CHF) * history of stroke * transient ischemic attack * carotid artery disease * myocardial ischemia * myocardial infarction * cardiomyopathy * implantable active medical device such as pacemaker or automatic defibrillator * Self-reported health conditions as identified in the Health Assessment Form * diabetes, * uncontrolled thyroid disease, * kidney disease / chronic renal impairment, * history of seizures (except childhood febrile seizures), * epilepsy, * history of unexplained syncope, * recent history of frequent migraine headaches, * recent symptomatic head injury (within the last 2 months), * Cancer requiring chemotherapy, radiation, or current treatment. * Participants with known clotting disorders (self-reported) * history of bleeding disorders or personal history of prolonged bleeding from injury * history of blood clots * hemophilia * current use of blood thinner: prescription or daily use of aspirin * Sickle Cell Trait or Disease * Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported) * Participants with severe allergies to iodine (only applicable if iodine is used) * Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine), * Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio \<0.4) * Unwillingness or inability to remove nail polish or artificial nails from test digits. * Surgical hardware in pathway of Device Under Test * Other known health conditions should be considered upon disclosure in health assessment form.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Device performance are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Element Materials Technology
Louisville, Colorado, 80027, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Wireless oxygen sensor for newborns put to the test
- Surgeons test wearing a VR headset instead of staring at a screen
- Can a single injection tame high triglycerides?
- Ancient exercise may hold key to stronger muscles in aging adults
- First human tests begin for new drug DW4421
- Plant-Powered study seeks to unlock gut health secrets